TRIM33
E3 ubiquitin-protein ligase TRIM33
Also known as: FLJ11429, KIAA1113, PTC7, RFG7, TF1G, TIF1G, TIF1GAMMA, TIFGAMMA, TRI33_HUMAN
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- Q9UPN9
- Gene
- TRIM33
- Ensembl
- ENSG00000197323
- Chromosome
- 1
- Canonical length
- 1127 aa
- Protein class
- Cancer-related genes, Disease related genes, Enzymes, Metabolic proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Vesicles
- Quaternary structure
- Homooligomer
OverviewNCBI Gene
The protein encoded by this gene is thought to be a transcriptional corepressor. However, molecules that interact with this protein have not yet been identified. The protein is a member of the tripartite motif family. This motif includes three zinc-binding domains, a RING, a B-box type 1 and a B-box type 2, and a coiled-coil region. Three alternatively spliced transcript variants for this gene have been described, however, the full-length nature of one variant has not been determined. [provided by RefSeq, Jul 2008]
Canonical amino-acid sequenceUniProt
1127 residues, UniProt reviewed canonical sequence.
>Q9UPN9|TRIM33
1 MAENKGGGEA ESGGGGSGSA PVTAGAAGPA AQEAEPPLTA VLVEEEEEEG GRAGAEGGAA
61 GPDDGGVAAA SSGSAQAASS PAASVGTGVA GGAVSTPAPA PASAPAPGPS AGPPPGPPAS
121 LLDTCAVCQQ SLQSRREAEP KLLPCLHSFC LRCLPEPERQ LSVPIPGGSN GDIQQVGVIR
181 CPVCRQECRQ IDLVDNYFVK DTSEAPSSSD EKSEQVCTSC EDNASAVGFC VECGEWLCKT
241 CIEAHQRVKF TKDHLIRKKE DVSESVGASG QRPVFCPVHK QEQLKLFCET CDRLTCRDCQ
301 LLEHKEHRYQ FLEEAFQNQK GAIENLLAKL LEKKNYVHFA ATQVQNRIKE VNETNKRVEQ
361 EIKVAIFTLI NEINKKGKSL LQQLENVTKE RQMKLLQQQN DITGLSRQVK HVMNFTNWAI
421 ASGSSTALLY SKRLITFQLR HILKARCDPV PAANGAIRFH CDPTFWAKNV VNLGNLVIES
481 KPAPGYTPNV VVGQVPPGTN HISKTPGQIN LAQLRLQHMQ QQVYAQKHQQ LQQMRMQQPP
541 APVPTTTTTT QQHPRQAAPQ MLQQQPPRLI SVQTMQRGNM NCGAFQAHQM RLAQNAARIP
601 GIPRHSGPQY SMMQPHLQRQ HSNPGHAGPF PVVSVHNTTI NPTSPTTATM ANANRGPTSP
661 SVTAIELIPS VTNPENLPSL PDIPPIQLED AGSSSLDNLL SRYISGSHLP PQPTSTMNPS
721 PGPSALSPGS SGLSNSHTPV RPPSTSSTGS RGSCGSSGRT AEKTSLSFKS DQVKVKQEPG
781 TEDEICSFSG GVKQEKTEDG RRSACMLSSP ESSLTPPLST NLHLESELDA LASLENHVKI
841 EPADMNESCK QSGLSSLVNG KSPIRSLMHR SARIGGDGNN KDDDPNEDWC AVCQNGGDLL
901 CCEKCPKVFH LTCHVPTLLS FPSGDWICTF CRDIGKPEVE YDCDNLQHSK KGKTAQGLSP
961 VDQRKCERLL LYLYCHELSI EFQEPVPASI PNYYKIIKKP MDLSTVKKKL QKKHSQHYQI
1021 PDDFVADVRL IFKNCERFNE MMKVVQVYAD TQEINLKADS EVAQAGKAVA LYFEDKLTEI
1081 YSDRTFAPLP EFEQEEDDGE VTEDSDEDFI QPRRKRLKSD ERPVHIKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against TRIM33 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.55
- Highest tissue expression
- 28 nTPM
Expression across tissuesHPA
Tissue
- epididymis: 28 nTPM
- bone marrow: 24 nTPM
- testis: 24 nTPM
- retina: 17 nTPM
- thymus: 17 nTPM
- placenta: 15 nTPM
Single-cell type
- neutrophils: 366 nCPM
- endometrial glandular cells: 327 nCPM
- neutrophil progenitors: 254 nCPM
- endometrial luminal cells: 237 nCPM
- late primary spermatocytes: 211 nCPM
- lactotrophs: 204 nCPM
Immune cell
- basophil: 13 nTPM
- eosinophil: 6.1 nTPM
- NK-cell: 4.1 nTPM
- neutrophil: 3.6 nTPM
- naive CD8 T-cell: 3.2 nTPM
- plasmacytoid DC: 3.1 nTPM
Brain region
- cerebellum: 55 nTPM
- cerebral cortex: 54 nTPM
- basal ganglia: 41 nTPM
- white matter: 40 nTPM
- hippocampal formation: 40 nTPM
- amygdala: 38 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about TRIM33.
Disease | AllUniProt
Conditions TRIM33 is implicated in, by any mechanism.
- Developmental dysplasia of the hip 4 (DDH4) MIM:621311
Disease | GeneticClinVar
2 pathogenic / likely-pathogenic of 109 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Developmental dysplasia of the hip
- Developmental dysplasia of the hip 4
Disease | AutoantibodyPubMed
Conditions in which antibodies against TRIM33 are reported. Each links to that disease's full target list.
- Dermatomyositis 103
- Myositis 42
- Lung Diseases, Interstitial 12
- Lung Neoplasms 8
- Polymyositis 5
- Adenocarcinoma 3
- Breast Neoplasms 3
Showing 7 of 9 — disease pages carrying at least 10 antigens.
ReferencesPubMed · IEDB
Publications for TRIM33 from three distinct lines of evidence, kept separate because they answer different questions: whether antibodies are directed at the protein, whether a B-cell epitope has been mapped on it, and whether a T-cell epitope has. Each is labelled with its source.
Reference: AutoantibodyPubMed
157 publications
- Most patients with cancer-associated dermatomyositis have antibodies to nuclear matrix protein NXP-2 or transcription intermediary factor 1γ.
2013 · Arthritis Rheum · RCR 10.6 · 298 citations - Myositis-specific anti-155/140 autoantibodies target transcription intermediary factor 1 family proteins.
2012 · Arthritis Rheum · RCR 8.2 · 231 citations - Autoantibodies in juvenile-onset myositis: Their diagnostic value and associated clinical phenotype in a large UK cohort.
2017 · J Autoimmun · RCR 7.3 · 146 citations - Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis.
2010 · Rheumatology (Oxford) · RCR 7.2 · 217 citations - Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1γ antibodies in adults with dermatomyositis.
2015 · J Am Acad Dermatol · RCR 6.8 · 139 citations
Show 20 more of 157 total
- Testing for myositis specific autoantibodies: Comparison between line blot and immunoprecipitation assays in 57 myositis sera.
2016 · J Immunol Methods · RCR 5.5 · 119 citations - Transcriptomic profiling reveals distinct subsets of immune checkpoint inhibitor induced myositis.
2023 · Ann Rheum Dis · RCR 5.4 · 50 citations - Anti-TIF1-γ antibody and cancer-associated myositis: A clinicohistopathologic study.
2016 · Neurology · RCR 4.4 · 96 citations - Immune responses to CCAR1 and other dermatomyositis autoantigens are associated with attenuated cancer emergence.
2022 · J Clin Invest · RCR 4.4 · 51 citations - Coexisting autoantibodies against transcription factor Sp4 are associated with decreased cancer risk in patients with dermatomyositis with anti-TIF1γ autoantibodies.
2023 · Ann Rheum Dis · RCR 4.3 · 33 citations - Oropharyngeal Dysphagia in Dermatomyositis: Associations with Clinical and Laboratory Features Including Autoantibodies.
2016 · PLoS One · RCR 3.9 · 71 citations - Anti-TIF1-γ autoantibodies: warning lights of a tumour autoantigen.
2020 · Rheumatology (Oxford) · RCR 3.7 · 56 citations - Use of Anti-transcriptional Intermediary Factor-1 Gamma Autoantibody in Identifying Adult Dermatomyositis Patients with Cancer: A Systematic Review and Meta-analysis.
2019 · Acta Derm Venereol · RCR 3.7 · 64 citations - Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis.
2016 · J Dermatol Sci · RCR 3.3 · 68 citations - Dermatomyositis unleashed by immune checkpoint inhibitors. Three additional cases and a review of the literature.
2023 · Autoimmun Rev · RCR 2.9 · 24 citations - Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis.
2021 · Ann Rheum Dis · RCR 2.8 · 41 citations - Nailfold capillaroscopy findings of a multicentric multi-ethnic cohort of patients with idiopathic inflammatory myopathies.
2024 · Clin Exp Rheumatol · RCR 2.7 · 9 citations - Myositis Specific Autoantibodies: A Clinical Perspective.
2020 · Open Access Rheumatol · RCR 2.6 · 31 citations - Myositis-specific and myositis-associated autoantibodies: their clinical characteristics and potential pathogenic roles.
2025 · Immunol Med · RCR 2.4 · 6 citations - Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies.
2019 · Mod Rheumatol · RCR 2.4 · 38 citations - The IgG2 Isotype of Anti-Transcription Intermediary Factor 1γ Autoantibodies Is a Biomarker of Cancer and Mortality in Adult Dermatomyositis.
2019 · Arthritis Rheumatol · RCR 1.9 · 33 citations - Myositis-specific autoantibodies and their clinical associations in idiopathic inflammatory myopathies.
2021 · Acta Neurol Scand · RCR 1.9 · 23 citations - The diagnostic work-up of cancer-associated myositis.
2018 · Curr Opin Rheumatol · RCR 1.9 · 34 citations - Investigating the disparities among drug categories in drug-induced dermatomyositis: A systematic review.
2024 · Semin Arthritis Rheum · RCR 1.8 · 4 citations - Circulating VEGF-A, TNF-α, CCL2, IL-6, and IFN-γ as biomarkers of cancer in cancer-associated anti-TIF1-γ antibody-positive dermatomyositis.
2023 · Clin Rheumatol · RCR 1.8 · 11 citations
Sources: PubMed — antigen-level antibody evidence from a custom retrieval. Records matching a controlled set of autoantibody terms (the MeSH descriptors Autoantibodies and Autoantigens, with title and abstract term variants) were obtained through NCBI E-utilities, and their titles and abstracts parsed for constructions that direct an antibody at a named protein rather than for co-occurrence. Captured names were resolved against UniProt nomenclature and each antigen adjudicated individually against the source text. Bibliographic records from PubMed and MeSH, U.S. National Library of Medicine; citation metrics from NIH iCite (Hutchins et al., PLoS Biology 2016). Titles link to PubMed; abstracts are not reproduced here. The NLM does not endorse this analysis.
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.09
- gnomAD pLI
- 1
- gnomAD missense Z
- 4.49
- DepMap mean gene effect
- -0.06
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- negative regulation of BMP signaling pathway
- negative regulation of DNA-templated transcription
- negative regulation of transcription by RNA polymerase II
- protein ubiquitination
- regulation of transforming growth factor beta receptor signaling pathway
Molecular functions
- co-SMAD binding
- DNA binding
- R-SMAD binding
- ubiquitin protein ligase activity
- ubiquitin-protein transferase activity
- zinc ion binding
Cellular components
Protein domainsUniProt · Pfam · InterPro
- B-box-type zinc finger
- Bromodomain
- Zinc finger, RING-type
- Zinc finger, PHD-type
- B-box, C-terminal
- Zinc finger, FYVE/PHD-type
- Zinc finger, RING/FYVE/PHD-type
- Zinc finger, RING-type, conserved site
- Zinc finger, PHD-type, conserved site
- Zinc finger, PHD-finger
- Bromodomain-like superfamily
- Bromodomain
- PHD-finger
- B-box zinc finger
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of TRIM33 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads TRIM33 as an antibody target. Whether an autoantibody or antibody against TRIM33 could matter depends on whether native TRIM33 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
TRIM33 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label TRIM33 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...